Drugs / Lysine Acetilsalicilate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT02929888 | Oct 2016 → Jul 2017 | acute myocardial infarction | Fundacion Investigacion Interhospitalaria Cardiovascular | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lysine Acetilsalicilate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02929888 ↗ |
| Known as | lysine acetylsalicylate | “However, evidence is lacked about the effects of achieving faster and stronger cyclooxygenase inhibition with intravenous lysine acetylsalicylate (LA) compared to oral aspirin.” NCT02929888 ↗ |
| Action | Inhibit | “faster and stronger cyclooxygenase inhibition with intravenous lysine acetylsalicylate (LA) compared to oral aspirin” NCT02929888 ↗ |
| Route | Intravenous | “intravenous LA 450mg” NCT02929888 ↗ |